Serotonin Transporter Gene Status and Electroconvulsive Therapy Outcomes: A Retrospective Analysis of 83 Patients
J Clin Psychiatry 2009;70(1):92-94
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The length of the promoter polymorphism of the serotonin transporter gene has been shown to have an impact on response to some selective serotonin reuptake inhibitor antidepressants. Carrier status for the long allele has been associated with a better response to serotonin reuptake inhibitor antidepressant medications in most studies.
Method: We retrospectively studied whether the allelic state was also associated with differential response to electroconvulsive therapy (ECT). Eighty-three ECT patients treated for unipolar or bipolar depression (based upon the treating psychiatrist's DSM-IV diagnosis) between July 2006 and September 2007 had allelic status testing at our facility. We determined whether serotonin transporter gene allelic status was associated with several aspects of ECT treatment, such as seizure length/threshold, number of treatments in a series, and depression scale ratings.
Results: We found no significant associations.
Conclusion: We conclude that currently available serotonin transporter gene long/short promoter polymorphism allelic status determination should not be used to guide clinical decisions about ECT.